Clinical Policy: Imiglucerase (Cerezyme)
Reference Number: CP.PHAR.154
Effective Date: 02.01.16
Last Review Date: 05.20
Line of Business: Commercial, HIM, Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Imiglucerase (Cerezyme®) is an analogue of the human enzyme β-glucocerebrosidase.

FDA Approved Indication(s)
Cerezyme is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of type 1 Gaucher disease (GD1) that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, or hepatomegaly or splenomegaly.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Cerezyme is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Gaucher Disease (must meet all):
      1. Diagnosis of Type 1 (GD1) or Type 3 Gaucher disease (GD3) confirmed by one of the following (a or b):
         a. Enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) activity;
         b. DNA testing;
      2. Age ≥ 2 years;
      3. Member is symptomatic (e.g., anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly);
      4. Cerezyme is not prescribed concurrently with Vpriv® (velaglucerase alfa) or Elelyso® (taliglucerase alfa).

   Approval duration:
   Medicaid/HIM – 6 months
   Commercial – 6 months or to the member’s renewal date, whichever is longer

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.
II. Continued Therapy

A. Gaucher Disease (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by increased or stabilized platelet count or hemoglobin, reduced or stabilized spleen or liver volume, decreased bone pain;
3. Cerezyme is not prescribed concurrently with Vpriv® (velaglucerase alfa) or Elelyso® (taliglucerase alfa).

Approval duration:
Medicaid/HIM – 12 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
ERT: enzyme replacement therapy
FDA: Food and Drug Administration
GD1: type 1 Gaucher disease
GD3: type 3 Gaucher disease

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): none reported.
- Boxed warning(s): none reported.

Appendix D: General Information
- Measures of Therapeutic Response: GD1 is a heterogeneous disorder which involves the visceral organs, bone marrow, and bone in almost all affected patients. Common conditions resulting from GD1 include anemia, thrombocytopenia, hepatomegaly,
spleenomegaly, and bone disease. Therefore, hemoglobin level, platelet count, liver volume, spleen volume, and bone pain are clinical parameters that can indicate therapeutic response to GD1 therapies. In some clinical trials, stability has been defined as the following thresholds of change from baseline: hemoglobin level < 1.5 g/dL decrease, platelet count < 25% decrease, liver volume < 20% increase, and spleen volume < 25% increase.

- Enzyme replacement therapy such as Cerezyme may have beneficial palliative effects in Type 2 disease, but does not alter the outcome and is not generally used.
- According to the European consensus guidelines revised recommendations on the management of neuronopathic Gaucher disease by Vellodi et al: (1) there is clear evidence in most patients that enzyme replacement therapy (ERT) ameliorates systemic involvement in non-neuronopathic (Type 1) as well as chronic neuronopathic Gaucher disease (Type 3), enhancing quality of life; (2) There is no evidence that ERT has reversed, stabilized or slowed the progression of neurological involvement; (3) In patients with established acute neuronopathic Gaucher disease (Type 2), enzyme replacement therapy has had little effect on the progressively downhill course. It has merely resulted in prolongation of pain and suffering.
- There is currently insufficient clinical evidence that supports the combination use of enzyme replacement therapy with Zavesca® (miglustat) or Cerdelga® (eliglustat), or concurrent use of two or more enzyme replacement therapies at once.

### V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gaucher Disease</td>
<td>Individualize to each patient; initial dose ranges from 2.5 U/kg via IV infusion 3 times a week to 60 U/kg once every 2 weeks; disease severity may dictate treatment be initiated at relatively high dose or relatively frequent administration</td>
<td>Individualized</td>
</tr>
</tbody>
</table>

### VI. Product Availability

- Vial: 200 units, 400 units

### VII. References

CLINICAL POLICY
Imiglucerase


Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1786</td>
<td>Injection, imiglucerase, 10 units</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Changes</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHAR.48.</td>
<td>01.16</td>
<td>02.16</td>
</tr>
<tr>
<td>Policy converted to new template.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age restriction removed. Allergy history removed as the drug can be continued in some cases. DNA testing added to diagnostic methods. ERT monotherapy added. Positive response to therapy added. Background section converted to new template.</td>
<td>12.16</td>
<td>02.17</td>
</tr>
<tr>
<td>Added age restriction. Modified requirement for presence of one of the following: anemia, thrombocytopenia, bone disease, or hepatomegaly or splenomegaly to require the presence of symptoms since other GD1 manifestations may be present which can also indicate need for initiation of enzyme replacement therapy (ERT). Added ERT monotherapy requirement for re-auth requests in addition to the initial criteria. Added appendix B.</td>
<td>08.24.17</td>
<td>11.17</td>
</tr>
<tr>
<td>2Q 2018 annual review: no significant changes from previously approved corporate policy; policies combined for Medicaid and Commercial lines of business; HIM added; Commercial: split from CP.CPA.241 Gaucher Disease Therapy policy; added age limit; removed maximum dose limit, as dosing is individualized per patient response to therapy; added the requirement that Cerezyme not be used concurrently with other enzyme replacement therapies; added specific examples of positive response to therapy, for reauthorization. Medicaid: added coverage for Type 3 Gaucher disease, as covered under the Commercial policy; references reviewed and updated.</td>
<td>02.25.18</td>
<td>05.18</td>
</tr>
<tr>
<td>2Q 2019 annual review: no significant changes; references reviewed and updated.</td>
<td>02.27.19</td>
<td>05.19</td>
</tr>
</tbody>
</table>
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.